Back to Search
GORDON SRKALOVIC, MD
MD
Hematology & Oncology Physician
NPI: 1780783282IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
4301082787(MI)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1981
Research & Publications (20)
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis.
PMID 16138931·Int Semin Surg Oncol·2005
8-other
Mycobacterium avium complex infection after alemtuzumab therapy for chronic lymphocytic leukemia.
PMID 18225973·Pharmacotherapy·2008
5-case
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
PMID 16818280·Haematologica·2006
4-observational
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PMID 16754936·J Clin Oncol·2006
3-trial
Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
PMID 16470606·Cancer·2006
3-trial
Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
PMID 16835968·Mayo Clin Proc·2006
3-trial
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
PMID 16980599·Ann Oncol·2006
3-trial
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PMID 16206291·Cancer·2005
3-trial
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
PMID 16342649·Mayo Clin Proc·2005
3-trial
Acute hypersensitivity reaction to ferric gluconate in a premedicated patient.
PMID 16288068·Ann Pharmacother·2005
5-case
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
PMID 15690325·Cancer·2005
4-observational
Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
PMID 15203282·Leuk Res·2004
8-other
Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
PMID 15274069·Cancer·2004
8-other
Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.
PMID 12916874·Leuk Lymphoma·2003
6-review
A phase 2 study of bortezomib in relapsed, refractory myeloma.
PMID 12826635·N Engl J Med·2003
3-trial
Undifferentiated thyroglobulin-positive thyroid cancer 45 years after treatment for papillary primary.
PMID 16224416·Clin Adv Hematol Oncol·2003
5-case
Acquired activated protein C resistance in myeloma patients with venous thromboembolic events.
PMID 14632794·Br J Haematol·2003
8-other
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
PMID 12491518·Cancer·2003
3-trial
A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
PMID 12412170·Cancer·2002
3-trial
Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
PMID 12512915·Med Oncol·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1215 E MICHIGAN AVE
LANSING, MI 48912 - Phone
- (517) 364-2890
Quick Facts
- NPI
- 1780783282
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 45
- Publications
- 20
Are you this provider?
Claim Your Profile